AIM ImmunoTech Inc (AMEX: AIM) is -58.40% lower on its value in year-to-date trading and has touched a low of $0.21 and a high of $0.62 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AIM stock was last observed hovering at around $0.23 in the last trading session, with the day’s loss setting it -0.05%.
Currently trading at $0.18, the stock is -26.04% and -29.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.26 million and changing -20.57% at the moment leaves the stock -49.18% off its SMA200. AIM registered -59.24% loss for a year compared to 6-month loss of -55.37%. The firm has a 50-day simple moving average (SMA 50) of $0.2634 and a 200-day simple moving average (SMA200) of $0.36155.
The stock witnessed a -30.92% gain in the last 1 month and extending the period to 3 months gives it a -53.54%, and is -23.75% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 24.24% over the week and 11.72% over the month.
AIM ImmunoTech Inc (AIM) has around 26 employees, a market worth around $11.66M and $0.19M in sales. Profit margin for the company is -12594.21%. Distance from 52-week low is -13.35% and -70.48% from its 52-week high. The company has generated returns on investments over the last 12 months (-686.04%).
with sales reaching $45k over the same period.The EPS is expected to grow by 42.22% this year, but quarterly earnings will post -25.74% year-over-year. Quarterly sales are estimated to shrink -30.77% in year-over-year returns.
AIM ImmunoTech Inc (AIM) Top Institutional Holders
33.0 institutions hold shares in AIM ImmunoTech Inc (AIM), with institutional investors hold 15.39% of the company’s shares. The shares outstanding are 63.71M, and float is at 58.21M with Short Float at 0.84%. Institutions hold 14.07% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 4.08 million shares valued at $1.52 million. The investor’s holdings represent 8.2454% of the AIM Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 1.99 million shares valued at $0.74 million to account for 4.021 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 0.7 million shares representing 1.4118% and valued at over $0.26 million, while GEODE CAPITAL MANAGEMENT, LLC holds 0.8108 of the shares totaling 0.4 million with a market value of $0.15 million.
AIM ImmunoTech Inc (AIM) Insider Activity
The most recent transaction is an insider purchase by Equels Thomas K, the company’s CEO & President. SEC filings show that Equels Thomas K bought 5,000 shares of the company’s common stock on Sep 16 ’24 at a price of $0.30 per share for a total of $1515.0. Following the purchase, the insider now owns 1.49 million shares.
AIM ImmunoTech Inc disclosed in a document filed with the SEC on Sep 13 ’24 that Equels Thomas K (CEO & President) bought a total of 20,000 shares of the company’s common stock. The trade occurred on Sep 13 ’24 and was made at $0.31 per share for $6160.0. Following the transaction, the insider now directly holds 1.49 million shares of the AIM stock.
Still, SEC filings show that on May 06 ’24, Equels Thomas K (CEO & President) acquired 61,729 shares at an average price of $0.41 for $25000.0. The insider now directly holds 778,184 shares of AIM ImmunoTech Inc (AIM).
